IPA's Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies

IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( "IPA") (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that BioStrand BV ("BioStrand"), an AI in silico discovery subsidiary of IPA, has entered into a research collaboration and license agreement (the "Agreement") with BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) ("BriaCell"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221130005423/en/

The collaboration will leverage BioStrand's LENSai™ software, built upon IPA's proprietary HYFT™ Universal Fingerprint™ technologies, and will focus on in silico antibody discovery to generate relevant clinical molecules for potential development. Under the terms of the Agreement, BioStrand and BriaCell will collaborate on the design, discovery, and development of anti-cancer antibodies. Upon successful antibody discovery, BioStrand will receive an upfront payment of US$500,000, and will be eligible to receive future success-based development milestones, including those for the submission of Investigational New Drugs (INDs), clinical milestone payments, and commercial royalties on net sales of products. Further terms are not disclosed.

"We are very excited to begin this program with BriaCell and apply our technology to the development of biologics that may have a huge clinical impact," stated Dr. Ingrid Brands, General Manager and co-founder of BioStrand. "Shortening timelines, while also integrating as much information as possible upstream to improve the efficiency of the process, is extremely important in the development of highly targeted therapies. It is a step towards realizing our long-term vision of significantly advancing precision medicine."

"We believe that BioStrand's revolutionary AI-powered technology, combined with its cutting-edge protein engineering platform, will allow us to design and discover potent anti-cancer therapeutics," stated Miguel A. Lopez-Lago, PhD, Chief Scientific Officer of BriaCell. "This approach would complement BriaCell's current immunotherapy pipeline of innovative anti-cancer therapeutics."

About BriaCell Therapeutics Corp.

BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at www. BriaCell.com

ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, Biostrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the "IPA Family"). The IPA Family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. Services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. For further information, visit www.ipatherapeutics.com .

Forward Looking Information

This news release contains forward-looking statements within the meaning of applicable United States securities laws and Canadian securities laws. Forward-looking statements are often identified by the use of words such as "potential", "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information contained in this news release include, but are not limited to, statements relating to the anticipated impact and results of IPA's collaboration with BriaCell as well as statements relating to the amount and timing of payments and commercial royalties to be received by BriaCell. In respect of the forward-looking information contained herein, IPA has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time.

Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the results of IPA's collaboration with BriaCell may not be as benefical as expected, milestones leading to payments from BriaCell may not all be met or at all, the amount of global net sales leading to commercial royalties may be less than expected; as well as those risks discussed in the Company's Annual Information Form dated July 28, 2022 (which may be viewed on the Company's profile at www.sedar.com ) and the Company's Form 40-F, dated July 29, 2022 (which may be viewed on the Company's profile at www.sec.gov ). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking information contained in this news release. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. The Company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221130005423/en/

( ImmunoPrecise Antibodies Ltd. ):

Investor: investors@ipatherapeutics.com

(BriaCell Therapeutics Corp.) :

William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com

Media Relations:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com

Investor Relations:
CORE IR
investors@briacell.com

News Provided by Business Wire via QuoteMedia

BriaCell TSX:BCT Emerging Tech Investing

BCT:CA

BriaCell Partners with New York Cancer & Blood Specialists for Pivotal Phase 3 Study of Bria-IMT in Advanced Breast Cancer

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce a partnership with New York Cancer & Blood Specialists (NYCBS), a group of leading community cancer centers in the United States, to evaluate the Bria-IMT™ combination with a checkpoint inhibitor in its pivotal Phase 3 registration study in advanced breast cancer patients in New York.

"Cancer is complex. It takes a village to care for a cancer patient. At NYCBS, our mission is to offer cancer patients access to state-of-the-art treatments close to their homes, families, and support networks at convenient locations across Long Island, New York City, and Upstate New York," stated Dr. Jeffrey Vacirca, CEO of NYCBS. "We were impressed with the survival data of the Bria-IMT™ regimen to date and look forward to working with the BriaCell team to make these novel therapeutics available to our patients."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT in Advanced Metastatic Breast Cancer

The randomized pivotal Phase 3 study is expected to enroll a total of 354 patients in either Bria-IMT™ combination or physician's choice therapy (1:1)
Positive results of the pivotal Phase 3 study could result in full approval and marketing authorization for Bria-IMT™
The study's primary endpoint is overall survival in patients treated with the Bria-IMT™ combination regimen versus those treated with physician's choice
The study initiation follows FDA Fast Track designation and earlier supportive Phase 2 safety and efficacy data in the same patient population

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces that its registration-enabling pivotal Phase 3 study of its lead clinical candidate, Bria-IMT™, in combination with an immune check point inhibitor, is fully approved by the Institutional Review Board (IRB) and will soon enroll patients with advanced metastatic breast cancer.

"Timely initiation of our pivotal study is a key milestone for us further confirming our expedited timeline for FDA approval of our immunotherapy," stated Dr. William V. Williams, BriaCell's President and CEO. "Based on our recently announced benchmark beating survival data, we strongly believe that our novel immunotherapy may transform the way we treat advanced metastatic breast cancer patients, and we look forward to sharing additional development milestones in the coming months."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

Median overall survival of 13.5 months in BriaCell's advanced metastatic breast cancer patients (vs. 6.7-9.8 months for similar patients reported in the literature)
21 out of 29 patients treated since 2022 are still alive suggesting a strong survival benefit for BriaCell's combination regimen
No dose limiting toxicities to date

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces the completion of patient enrollment in its Phase 2 clinical study and reports clinical data showing strong patient survival benefit and clinical benefit in advanced metastatic breast cancer patients.

"The promising survival data of BriaCell's combination regimen suggests the potential for an industry-shaping leap in advanced metastatic breast cancer treatment," stated Carmen Calfa, M.D., of the Sylvester Comprehensive Cancer Center at the University of Miami, Associate Professor of Clinical Medicine, and Principal Clinical Investigator of the Phase 2 Bria-IMT™ plus check point inhibitors study. "The overall safety profile and survival data in advanced metastatic breast cancer is extremely encouraging in this heavily pre-treated patient population."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders

briacell therapeutics corp. closes Arrangement effecting the distribution described in the plan of arrangement.

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (" BriaCell " or the " Company "), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces that the Company has closed the previously announced plan of arrangement spinout transaction (the " Arrangement ") pursuant to which certain pipeline assets of the Company, including Bria-TILsRx™ and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer (the " SpinCo Assets "), were spun-out to BriaPro Therapeutics Corp. (" SpinCo "), resulting in a 23 rd owned subsidiary of the Company with the remaining 13 rd held by BriaCell shareholders (" BriaCell Shareholders ").

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT in High-Risk Early-Stage Triple Negative Breast Cancer

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that it has accepted a letter of intent from Dr. Massimo Cristofanilli, Director of Breast Medical Oncology and Associate Director of Precision Medicine in the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, outlining the parties' plans and commitment, upon regulatory approval, to initiate a Phase 2 investigator-initiated clinical study to evaluate BriaCell's novel immunotherapy, Bria-IMT™, in combination with a check point inhibitor (CPI), in early stage, newly diagnosed, high-risk triple negative breast cancer (TNBC) patients in the neoadjuvant setting.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Nextech3D.ai Expands Offering to Ecommerce Imagery: Unveils Cutting-Edge 3D Model-AI Photo Rendering Services, Transforming 2D Photos into Dynamic Product Visuals

New ecommerce expansion with AI 3D-Photography Tools

Nextech3D.ai (OTCQX:NEXCF)(CSE:NTAR)(FSE:EP2), a patented 2D-3D Generative AI-Powered 3D model supplier (Patent #11,948,248) for Amazon, Miele, P&G, Kohls, Wesfarmers Group ``Bunnings" (Australia's largest listed company) and other major e-commerce retailers is adding Digital Photography and dynamic product visuals as part of its 3D model offerings. Now every 3D model that Nextech3D.ai creates will have stunning 2K, 4K, or even 8K photos to go with it for its ecommerce customers. This AI tool is expected to drive significant revenue for the company as each product listed for sale on an ecommerce platform requires a minimum of six 2D photos for listing, this offering allows the company to capitalize on this demand for 2D high res images while simultaneously increases the value of its 3D modeling business as it represents the all-in-one solutions for ecommerce sellers that sell on Amazon, Shopify and other platforms. The company has already signed up 10 existing customers for its digital photography offering representing over 6000+digital photos and will be offering it both as part of a 3D model bundle as well as a stand alone product offering for people that already have a 3D model opening up the ecommerce imagery market to the company. The company's analysis shows that creating and rendering 3D models is more cost-effective than traditional product photography, especially for products that are expensive to produce or difficult to photograph in real life. Once a 3D model is created, it can be easily manipulated and rendered from different angles without the need for physical prototypes or multiple photoshoots

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Aether Global Provides Update on Management Cease Trade Order

(TheNewswire)

Vancouver, B.C. TheNewswire - April 17, 2024 Aether Global Innovations Corp. (CSE:AETH) (OTC:AETHF) (Frankfurt:4XA) (WKN#A2N8RH), a leader in drone management and automation, is providing this update on the status of a management cease trade order (the "MCTO") granted on April 3, 2024 by the British Columbia Securities Commission under National Policy 12-203 - Management Cease Trade Order ("NP 12-203").

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

NEO Battery Materials Appoints Renowned Battery Industry Pioneer Mr. Ricky Lee as Lead Managerial Advisor

T S X V : NBM ) ( OTC: NBMFF )

NEO Battery Materials Ltd. (" NEO " or the " C o mpan y "), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to appoint Mr. Ricky Lee, a renowned battery industry pioneer, as the Lead Managerial Advisor. Mr. Ricky Lee is a 35-year battery and energy industry executive with substantial experience with battery material and cell design, mass-production technology, and equipment & process development at globally distinguished companies.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

ARway.ai Signs Deal with George Mason University for Augmented Reality Campus Navigation and Experience

ARway.ai ("ARway" or the "Company") (CSE:ARWY)(OTCQB:ARWYF)(FSE:E65) is an AI powered Augmented Reality Experience platform with a disruptive no-code, no beacon spatial computing solution enabled by visual marker tracking with centimeter precision is pleased to announce that George Mason University is signed up for the ARway platform and will be deploying ten spatial maps across the university campus. The rollout is part of a 2024 project aimed at enhancing the campus navigation and campus experience for students. GMU has an undergraduate enrollment of approximately 27,014 and the campus size is 817 acres. ARway.ai is seeing demand from across the globe for University Campus deployments, and is currently deployed in the Middle East at the Suleyman Demirel University in Turkey, In the EU at the Institut für Innovations- und Informationsmanagement (iFii), University of Applied Sciences Brandenburg. ARway has also signed multiple new subscriptions with prestigious universities around the globe including Bicol University in Indonesia, DHA Suffa University in Pakistan, University of Alberta in Canada, University College Cork in the UK and German University of Technology in Oman

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Cypher Metaverse Inc. Announces Debt Settlements

Cypher Metaverse Inc. (CSE:CODE) ("CODE" or the "Company") announces today that it has entered into settlement agreements that will see $149,215 of debt settled by the issuance of 1,755,470 shares at a deemed price of $0.085, and the Company's balance sheet much improved

No finders fees will be paid. The securities issued will be subject to a four-month and one-day hold period from closing.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Sona Nanotech Provides Interim Results of Dalhousie Efficacy Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce further positive interim results from its study with The Giacomantonio Immuno-Oncology Research Group at Dalhousie University (the "Study"). The Company was provided with data from the Study that indicates the response in a pre-clinical triple negative breast cancer model treated with the combination of Sona's targeted hyperthermia therapy ("THT") and interleukin-2 ("IL-2"), a standard immunotherapy, is statistically significantly superior to results observed from treatment with either agent individually or the control group. This second phase of the Study has documented that, in a cohort of six animals, 66 of treated triple negative breast cancer, the most aggressive and therapy resistant form, mouse tumors bearing gold nanorods and IL-2 responded to the combination therapy, resulting in a flattening of the tumor growth curves, as shown in the below graph. The generation of hyperthermia involved exposing tumors previously injected intratumorally with Sona's gold nanorods and IL-2 to a single dose of near infrared light.